Patents by Inventor Xiaoxia Zheng

Xiaoxia Zheng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250066199
    Abstract: A carbonaceous material contains element O, where the content of element O of the carbonaceous material tested by X-ray photoelectron spectroscopy is denoted as A, the content of element O of the carbonaceous material tested by elemental analysis is denoted as B, and the carbonaceous material satisfies A/B?3 and 5 wt %?A?20 wt %.
    Type: Application
    Filed: November 13, 2024
    Publication date: February 27, 2025
    Inventors: Xiaoxia CHEN, Yu MA, Xinxin ZHANG, Chuying OUYANG, Xiaoji ZHENG, Shangdong CHEN, Wenguang LIN
  • Publication number: 20250059044
    Abstract: A carbonaceous material where in the CO2 adsorption test of the carbonaceous material, the total CO2 adsorption at 0° C. and a relative pressure P/P0 between 10?8 and 0.029 is recorded as A, the adsorption time is recorded as B, and the carbonaceous material satisfies: A/B?1.7 cm3/(g×h) STP, where STP is the standard condition, P represents the test pressure of CO2, and P0 represents the saturated vapor pressure of CO2 at 0° C.
    Type: Application
    Filed: October 31, 2024
    Publication date: February 20, 2025
    Inventors: Xiaoxia CHEN, Xinxin ZHANG, Chuying OUYANG, Yu MA, Xiaolong LI, Xiaoji ZHENG, Wenguang LIN, Shangdong CHEN
  • Publication number: 20250059045
    Abstract: A carbonaceous material has an adsorption velocity v that satisfies 0.015?v?0.050 when subjected to an adsorption test using water vapor at a constant temperature and humidity of 25° C. and 40% RH. The water vapor adsorption test is performed under the following conditions: in a constant temperature and humidity chamber at 25° C. and 40% RH, the carbonaceous material with a mass of m1 is placed in a container, and a water vapor adsorption mass m2 and a water vapor adsorption time t are recorded when the water vapor adsorption of the carbonaceous material reaches equilibrium, and the water vapor adsorption velocity is v=m2/(m1×t), where mi is measured in g, m2 is measured in g, and t is measured in h.
    Type: Application
    Filed: November 8, 2024
    Publication date: February 20, 2025
    Inventors: Yu MA, Xinxin ZHANG, Xiaoxia CHEN, Chuying OUYANG, Wenguang LIN, Shangdong CHEN, Weiming CHENG, Xiaoji ZHENG
  • Patent number: 12207274
    Abstract: Methods, systems, and devices for signaling for transmission configuration indication (TCI) state activation for multiple transmission reception points are described. A user equipment (UE) may receive at least one control message indicating a first set of beam configurations associated with a first downlink shared channel from a first transmission reception point (TRP) and a second set of beam configurations associated with a second downlink shared channel from a second TRP. The UE may receive downlink control information (DCI) from the first and second TRPs indicating a first beam configuration of the first set of beam configurations and a second beam configuration of the second set of beam configurations, respectively. The UE may subsequently decode a first downlink transmission from the first downlink shared channel according to the first beam configuration and a second downlink transmission from the second downlink shared channel according to the second beam configuration.
    Type: Grant
    Filed: January 13, 2021
    Date of Patent: January 21, 2025
    Assignee: QUALCOMM Incorporated
    Inventors: Ruiming Zheng, Mostafa Khoshnevisan, Linhai He, Xiaoxia Zhang
  • Publication number: 20240424175
    Abstract: Devices, systems, and methods are provided including a structure having one or more surfaces configured for internal use within a patient's body and one or more therapeutic compositions comprising one or more active substances including at least one of a chelating agent, a direct factor Xa inhibitor, a direct factor IIa inhibitor, and a factor XI/XIa inhibitor disposed in or on the structure. The structure is configured to be positioned adjacent a target site in the patient's body. The therapeutic composition is formulated to release the one or more active substances to the target site to provide one or more of inhibit clot formation, promote clot dissolution, inhibit or dissolute inflammation, inhibit vessel injury, increase time before clotting, and/or inhibit cell proliferation. Delayed or other controlled release of the therapeutic composition from the structure may be provided.
    Type: Application
    Filed: May 23, 2024
    Publication date: December 26, 2024
    Applicant: Elixir Medical Corporation
    Inventors: John YAN, Xiaoxia ZHENG, Vinayak D. BHAT, Motasim SIRHAN
  • Publication number: 20240074882
    Abstract: The disclosure provides biodegradable implantable devices such as a stent comprising a biodegradable polymeric material wherein the polymeric material is treated to control crystallinity and/or Tg. The stent is capable of expanding at body temperature in a body lumen from a crimped configuration to a deployed diameter and will have sufficient strength to support a body lumen when expanded.
    Type: Application
    Filed: March 30, 2022
    Publication date: March 7, 2024
    Applicant: Elixir Medical Corporation
    Inventors: Xiaoxia Zheng, John Yan, Vinayak Bhat
  • Publication number: 20230293540
    Abstract: Devices, formulations, compositions, and methods are provided for inhibiting an inflammatory ophthalmic disease or eye condition in a patient. A therapeutic composition comprising a direct factor Xa inhibitor and/or a direct factor II inhibitor is provided. A therapeutically effective dose of the therapeutic composition is delivered to a site of the inflammatory ophthalmic disease or condition in the patient’s eye(s). The therapeutic composition may be formulated for delivery to the patient by via injection, an implant, an eye drop, an emulsion, a suspension, an ointment, a nanomicelle, a nanoparticle, a nanosuspension, a liposome, an in-situ gel, a contact lens, or a microneedle or the like. The therapeutic composition may include one or more additional therapeutically active substances and/or one or more additional pharmaceutical agents.
    Type: Application
    Filed: March 6, 2023
    Publication date: September 21, 2023
    Applicant: Elixir Medical Corporation
    Inventors: John Yan, Xiaoxia Zheng, Vinayak D. Bhat, Motasim Sirhan, Margaret Wong, Blaine Bueche
  • Publication number: 20230190499
    Abstract: Devices, systems, and methods are provided including a structure having one or more surfaces configured for internal use within a patient's body and one or more therapeutic compositions comprising one or more active substances including a direct factor Xa inhibitor, and a direct factor IIa inhibitor disposed in or on the structure. The structure is configured to be positioned adjacent an injury site in the patient's body. The one or more active substances optionally include an anti-proliferative agent. The therapeutic composition is formulated to release the one or more active substances to the injury site to provide one or more of inhibit clot formation, promote clot dissolution, inhibit or dissolute inflammation, inhibit vessel injury, increase time before clotting, and/or inhibit cell proliferation.
    Type: Application
    Filed: February 6, 2023
    Publication date: June 22, 2023
    Applicant: Elixir Medical Corporation
    Inventors: Motasim Sirhan, Xiaoxia Zheng, Vinayak D. Bhat, John Yan
  • Publication number: 20230165874
    Abstract: Devices, compositions, and methods are provided for inhibiting an inflammatory, fibrotic, and/or clot formation for pulmonary disease or condition in a patient. A therapeutic composition comprising a direct factor Xa inhibitor and/or a direct factor IIa inhibitor is provided. A therapeutically effective dose of the therapeutic composition is delivered to a site of the inflammatory, fibrotic, and/or clot formation pulmonary disease or condition in the patient's lung(s). The therapeutic composition may be formulated for delivery to the patient by inhalation, ventilation, instillation, ultrasound, vibration, injection, or the like. The therapeutic composition may include one or more additional therapeutically active substances and/or one or more additional pharmaceutical agents.
    Type: Application
    Filed: January 27, 2023
    Publication date: June 1, 2023
    Applicant: Elixir Medical Corporation
    Inventors: John Yan, Xiaoxia Zheng, Vinayak D. Bhat, Motasim Sirhan, Blaine Bueche
  • Publication number: 20230165839
    Abstract: The present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula: wherein R1, R2, R3, R5, R6, R8, M1, M2, M3, M4, M5, M6 and M7 are each independently a member selected from the group consisting of H, C1-6 alkyl, OH and C1-6 hydroxyalkyl; R4, R7 and R9 are each independently selected from the group consisting of C1-6 alkoxy and OH; R10 is a member selected from the group consisting of H, —OH, —OP(O)Me2, —O—(CH2)n—OH and —O—(CH2)m—O—(CH2)o—CH3, wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; each of L1 and L4 are independently selected from the group consisting of: wherein each M8 is independently a member selected from the group consisting of C1-6 alkyl, OH and C1-6 hydroxyalkyl; each of L2 and L3 are independently selected from the group consisting of: and salts, hydrates, isomers, metabolites, N-oxides and prodrugs thereof.
    Type: Application
    Filed: September 9, 2022
    Publication date: June 1, 2023
    Applicant: Elixir Medical Corporation
    Inventors: John Yan, Xiaoxia Zheng, Vinayak D. Bhat
  • Patent number: 11654036
    Abstract: Devices, systems, and methods are provided including a structure having one or more surfaces configured for internal use within a patient's body and one or more therapeutic compositions comprising one or more active substances including a direct factor Xa inhibitor, and a direct factor IIa inhibitor disposed in or on the structure. The structure is configured to be positioned adjacent an injury site in the patient's body. The one or more active substances optionally include an anti-proliferative agent. The therapeutic composition is formulated to release the one or more active substances to the injury site to provide one or more of inhibit clot formation, promote clot dissolution, inhibit or dissolute inflammation, inhibit vessel injury, increase time before clotting, and/or inhibit cell proliferation.
    Type: Grant
    Filed: August 13, 2021
    Date of Patent: May 23, 2023
    Assignee: Elixir Medical Corporation
    Inventors: Motasim Sirhan, Xiaoxia Zheng, Vinayak D. Bhat, John Yan
  • Publication number: 20220039976
    Abstract: Devices, systems, and methods are provided including a structure having one or more surfaces configured for internal use within a patient's body and one or more therapeutic compositions comprising one or more active substances including a direct factor Xa inhibitor, and a direct factor IIa inhibitor disposed in or on the structure. The structure is configured to be positioned adjacent an injury site in the patient's body. The one or more active substances optionally include an anti-proliferative agent. The therapeutic composition is formulated to release the one or more active substances to the injury site to provide one or more of inhibit clot formation, promote clot dissolution, inhibit or dissolute inflammation, inhibit vessel injury, increase time before clotting, and/or inhibit cell proliferation.
    Type: Application
    Filed: August 13, 2021
    Publication date: February 10, 2022
    Applicant: Elixir Medical Corporation
    Inventors: John Yan, Xiaoxia Zheng, Vinayak D. Bhat, Motasim Sirhan
  • Publication number: 20210008040
    Abstract: The present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula: wherein R1, R2, R3, R5, R6, R8, M1, M2, M3, M4, M5, M6 and M7 are each independently a member selected from the group consisting of H, C1-6 alkyl, —OH and C1-6 hydroxyalkyl; R4, R7 and R9 are each independently selected from the group consisting of C1-6 alkoxy and OH; R10 is a member selected from the group consisting of H, —OH, —OP(O)Me2, —O—(CH2)n—OH and —O—(CH2)m—O—(CH2)o—CH3, wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; each of L1 and L4 are independently selected from the group consisting of: wherein each M8 is independently a member selected from the group consisting of C1-6 alkyl, OH and C1-6 hydroxyalkyl; each of L2 and L3 are independently selected from the group consisting of: and salts, hydrates, isomers, metabolites, N-oxides and prodrugs thereof.
    Type: Application
    Filed: May 20, 2020
    Publication date: January 14, 2021
    Applicant: Elixir Medical Corporation
    Inventors: John Yan, Xiaoxia Zheng, Vinayak D. Bhat
  • Patent number: 10695327
    Abstract: A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula: wherein R1, R2, R3, R5, R6, R8, M1, M2, M3, M4, M5, M6 and M7 are each independently a member selected from the group consisting of H, C1-6 alkyl, OH and C1-6 hydroxyalkyl; R4, R7 and R9 are each independently selected from the group consisting of C1-6 alkoxy and OH; R10 is a member selected from the group consisting of H, —OH, —OP(O)Me2, —O—(CH2)n—OH and —O—(CH2)m—O—(CH2)o—CH3, wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; each of L1 and L4 are independently selected from the group consisting of: wherein each M8 is independently a member selected from the group consisting of C1-6 alkyl, OH and C1-6 hydroxyalkyl; each of L2 and L3 are independently selected from the group consisting of: and salts, isomers, or N-oxides thereof.
    Type: Grant
    Filed: October 8, 2018
    Date of Patent: June 30, 2020
    Assignee: Elixir Medical Corporation
    Inventors: John Yan, Xiaoxia Zheng, Vinayak D. Bhat
  • Publication number: 20200093619
    Abstract: The disclosure provides biodegradable implantable devices such as a stent comprising a biodegradable polymeric wherein the polymeric material is treated to control crystallinity and/or Tg. The stent is capable to expand at body temperature in a body lumen from a crimped configuration to a deployed diameter and have sufficient strength to support a body lumen.
    Type: Application
    Filed: February 20, 2018
    Publication date: March 26, 2020
    Applicant: Elixir Medical Corporation
    Inventors: Xiaoxia Zheng, John Yan, Vinayak Bhat
  • Publication number: 20190275013
    Abstract: The present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula: wherein R1, R2, R3, R5, R6, R8, M1, M2, M3, M4, M5, M6 and M7 are each independently a member selected from the group consisting of H, C1-6 alkyl, OH and C1-6 hydroxyalkyl; R4, R7 and R9 are each independently selected from the group consisting of C1-6 alkoxy and OH; R10 is a member selected from the group consisting of H, —OH, —OP(O)Me2, —O—(CH2)n—OH and —O—(CH2)m—O—(CH2)o—CH3, wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; each of L1 and L4 are independently selected from the group consisting of: wherein each M8 is independently a member selected from the group consisting of C1-6 alkyl, OH and C1-6 hydroxyalkyl; each of L2 and L3 are independently selected from the group consisting of: and salts, hydrates, isomers, metabolites, N-oxides and prodrugs thereof.
    Type: Application
    Filed: October 8, 2018
    Publication date: September 12, 2019
    Applicant: Elixir Medical Corporation
    Inventors: John Yan, Xiaoxia Zheng, Vinayak D. Bhat
  • Patent number: 10123996
    Abstract: A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula: wherein R1, R2, R3, R5, R6, R8, M1, M2, M3, M4, M5, M6 and M7 are each independently a member selected from the group consisting of H, C1-6 alkyl, OH and C1-6 hydroxyalkyl; R4, R7 and R9 are each independently selected from the group consisting of C1-6 alkoxy and OH; R10 is a member selected from the group consisting of H, —OH, —OP(O)Me2, —O—(CH2)n—OH and —O—(CH2)m—O—(CH2)o—CH3, wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; each of L1 and L4 are independently selected from the group consisting of: wherein each M8 is independently a member selected from the group consisting of C1-6 alkyl, OH and C1-6 hydroxyalkyl; each of L2 and L3 are independently selected from the group consisting of: and salts, isomers, or N-oxides thereof.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: November 13, 2018
    Assignee: Elixir Medical Corporation
    Inventors: John Yan, Xiaoxia Zheng, Vinayak D. Bhat
  • Publication number: 20170156899
    Abstract: The disclosure provides biodegradable implantable devices such as a stent comprising a biodegradable polymeric wherein the polymeric material is treated to control crystallinity and/or Tg. The stent is capable to expand at body temperature in a body lumen from a crimped configuration to a deployed diameter and have sufficient strength to support a body lumen.
    Type: Application
    Filed: January 31, 2017
    Publication date: June 8, 2017
    Applicant: Elixir Medical Corporation
    Inventors: Xiaoxia Zheng, John Yan, Vinayak Bhat
  • Publication number: 20170119741
    Abstract: The present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula: wherein R1, R2, R3, R5, R6, R8, M1, M2, M3, M4, M5, M6 and M7 are each independently a member selected from the group consisting of H, C1-6 alkyl, OH and C1-6 hydroxyalkyl; R4, R7 and R9 are each independently selected from the group consisting of C1-6 alkoxy and OH; R10 is a member selected from the group consisting of H, —OH, —OP(O)Me2, —O—(CH2)n—OH and —O—(CH2)m—O—(CH2)o—CH3, wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; each of L1 and L4 are independently selected from the group consisting of: wherein each M8 is independently a member selected from the group consisting of C1-6 alkyl, OH and C1-6 hydroxyalkyl; each of L2 and L3 are independently selected from the group consisting of: and salts, hydrates, isomers, metabolites, N-oxides and prodrugs thereof.
    Type: Application
    Filed: June 13, 2016
    Publication date: May 4, 2017
    Inventors: John Yan, Xiaoxia Zheng, Vinayak D. Bhat
  • Patent number: 9566371
    Abstract: The disclosure provides biodegradable implantable devices such as a stent comprising a biodegradable polymeric wherein the polymeric material is treated to control crystallinity and/or Tg. The stent is capable to expand at body temperature in a body lumen from a crimped configuration to a deployed diameter and have sufficient strength to support a body lumen.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: February 14, 2017
    Assignee: Elixir Medical Corporation
    Inventors: Xiaoxia Zheng, John Yan, Vinayak Bhat